中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(5): 844-850

Interpretation of guideline for diagnosis and treatment of acute-on-chronic liver failure （2025 edition）

DOI: 10.12449/JCH250508
  • 1.

    Fourth Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

  • 2.

    Department of Gastroenterology，The First Affiliated Hospital of Nankai University （Tianjin People’s Hospital），Tianjin 300121，China

Research funding:

Capital’s Funds for Health Improvement and Research (CFH2024-1-2181);

Construction Project of High-level Technology Talents in Public Health (Discipline leader-01-12);

Beijing Hospitals Authority’‍s Ascent Plan (DFL20221501);

National Key Research and Development Program of China (2022YFC2304402)

More Information
  • Corresponding author: DUAN Zhongping， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）; HAN Tao， hantaomd@126.com （ORCID： 0000-0003-4216-6968）; CHEN Yu， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）
  • Received Date: 2025-05-01
  • Accepted Date: 2025-05-10
  • Published Date: 2025-05-25
    Abstract
  • In 2025， Severe Liver Disease and Artificial Liver Group and Nutrition and Regeneration in End-Stage Liver Disease Group of Chinese Society of Hepatology， Chinese Medical Association， convened a panel of national experts to jointly develop China’s first guideline for the diagnosis and treatment of acute-on-chronic liver failure （ACLF）. Based on the latest research findings and clinical practice in China and globally， this guideline establishes a standardized definition of ACLF and provide recommendations for its diagnosis， treatment， and clinical management. This article gives an interpretation of the key points in the guideline， in order to provide a reference for standardized diagnosis and treatment of ACLF.

     

    • FullText(HTML)
  • loading
    • References(59)
  • [1]
    BR VK, SARIN SK. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29( 3): 670- 689. DOI: 10.3350/cmh.2022.0103.
    [2]
    AGGARWAL A, BISWAS S, ARORA U, et al. Definitions, etiologies, and outcomes of acute on chronic liver failure: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2024, 22( 11): 2199- 2210. e 25. DOI: 10.1016/j.cgh.2024.04.018.
    [3]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis, 2008, 1( 1): 47- 53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病人工肝学组. 肝衰竭诊疗指南[J]. 中华临床感染病杂志, 2008, 1( 1): 47- 53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014.
    [4]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2012)[J]. Chin J Clin Infect Dis, 2012, 5( 6): 321- 327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 中华临床感染病杂志, 2012, 5( 6): 321- 327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001.
    [5]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [6]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
    [7]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. Chin J Hepatol, 2025, 33( 4): 329- 339. DOI: 10.3760/cma.j.cn501113-20250312-00089.

    中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版)[J]. 中华肝脏病杂志, 2025, 33( 4): 329- 339. DOI: 10.3760/cma.j.cn501113-20250312-00089.
    [8]
    OHNISHI H, SUGIHARA J, MORIWAKI H, et al. Acute-on-chronic liver failure[J]. Ryoikibetsu Shokogun Shirizu, 1995( 7): 217- 219.
    [9]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
    [10]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 2): 461- 491. DOI: 10.1016/j.jhep.2023.04.021.
    [11]
    BAJAJ JS, O’LEARY JG, REDDY KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60( 1): 250- 256. DOI: 10.1002/hep.27077.
    [12]
    BAJAJ JS, O’LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117( 2): 225- 252. DOI: 10.14309/ajg.0000000000001595.
    [13]
    KARVELLAS CJ, BAJAJ JS, KAMATH PS, et al. AASLD Practice Guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis[J]. Hepatology, 2024, 79( 6): 1463- 1502. DOI: 10.1097/HEP.0000000000000671.
    [14]
    CHOUDHURY A, KULKARNI AV, ARORA V, et al. Acute-on-chronic liver failure(ACLF): The‘Kyoto consensus’-steps from Asia[J]. Hepatol Int, 2025, 19( 1): 1- 69. DOI: 10.1007/s12072-024-10773-4.
    [15]
    CLÀRIA J, ARROYO V, MOREAU R. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5( 9): 100807. DOI: 10.1016/j.jhepr.2023.100807.
    [16]
    ENGELMANN C, CLÀRIA J, SZABO G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021, 75( Suppl 1): S49- S66. DOI: 10.1016/j.jhep.2021.01.002.
    [17]
    SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL) 2014[J]. Hepatol Int, 2014, 8( 4): 453- 471. DOI: 10.1007/s12072-014-9580-2.
    [18]
    XU MM, LI SS, YANG YR, et al. Epidemiological characteristics of inpatients with liver failure at the Beijing You’an Hospital from 2012 to 2021[J]. Chin J Hepatol, 2024, 32( 1): 49- 57. DOI: 10.3760/cma.j.cn501113-20220824-00433.

    徐曼曼, 李珊珊, 杨颜榕, 等. 2012至2021年北京佑安医院肝衰竭住院患者流行病学特征[J]. 中华肝脏病杂志, 2024, 32( 1): 49- 57. DOI: 10.3760/cma.j.cn501113-20220824-00433.
    [19]
    XU MM, CHEN Y. New perspectives in the definition and classification of acute-on-chronic liver failure[J]. Chin Med J(Engl), 2024, 137( 21): 2521- 2525. DOI: 10.1097/CM9.0000000000003289.
    [20]
    XU MM, KONG M, YU PF, et al. Clinical course and outcome patterns of acute-on-chronic liver failure: A multicenter retrospective cohort study[J]. J Clin Transl Hepatol, 2021, 9( 5): 626- 634. DOI: 10.14218/JCTH.2020.00179.
    [21]
    SCHWARZ M, SIMBRUNNER B, JACHS M, et al. High histamine levels are associated with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease[J]. Liver Int, 2024, 44( 11): 2904- 2914. DOI: 10.1111/liv.16056.
    [22]
    MO RD, ZHANG ZL, ZHOU YM, et al. A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis[J]. Lipids Health Dis, 2025, 24( 1): 35. DOI: 10.1186/s12944-025-02434-8.
    [23]
    ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
    [24]
    HU CH, JIANG N, ZHENG J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 12): 1253- 1263. DOI: 10.1002/jhbp.1112.
    [25]
    KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
    [26]
    KIM WR, BIGGINS SW, KREMERS WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list[J]. N Engl J Med, 2008, 359( 10): 1018- 1026. DOI: 10.1056/NEJMoa0801209.
    [27]
    JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61( 5): 1038- 1047. DOI: 10.1016/j.jhep.2014.06.012.
    [28]
    LI JQ, LIANG X, YOU SL, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75( 5): 1104- 1115. DOI: 10.1016/j.jhep.2021.05.026.
    [29]
    CHOUDHURY A, JINDAL A, MAIWALL R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure(ACLF): Comparison of APASL ACLF research consortium(AARC) and CLIF-SOFA models[J]. Hepatol Int, 2017, 11( 5): 461- 471. DOI: 10.1007/s12072-017-9816-z.
    [30]
    O’LEARY JG, REDDY KR, GARCIA-TSAO G, et al. NACSELD acute-on-chronic liver failure(NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis[J]. Hepatology, 2018, 67( 6): 2367- 2374. DOI: 10.1002/hep.29773.
    [31]
    GUSTOT T, FERNANDEZ J, GARCIA E, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology, 2015, 62( 1): 243- 252. DOI: 10.1002/hep.27849.
    [32]
    YU ZJ, ZHANG Y, CAO YY, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators[J]. Sci Rep, 2021, 11( 1): 1810. DOI: 10.1038/s41598-021-81431-0.
    [33]
    MENG QH, HOU W, YU HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure[J]. J Clin Gastroenterol, 2011, 45( 5): 456- 461. DOI: 10.1097/MCG.0b013e31820f7f02.
    [34]
    CHEUNG K, LEE SS, RAMAN M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies[J]. Clin Gastroenterol Hepatol, 2012, 10( 2): 117- 125. DOI: 10.1016/j.cgh.2011.08.016.
    [35]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.

    中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
    [36]
    YAO J, ZHOU XS, WANG H, et al. Persistently increased resting energy expenditure predicts short-term mortality in patients with acute-on-chronic liver failure[J]. Ann Nutr Metab, 2018, 73( 1): 2- 9. DOI: 10.1159/000487604.
    [37]
    LIU X, KONG M, HUA X, et al. Effects of an individualized nutritional intervention on the prognosis of patients with liver failure[J]. Asia Pac J Clin Nutr, 2022, 31( 2): 215- 221. DOI: 10.6133/apjcn.202206_31(2).0007.
    [38]
    KUMAR R, PRAKASH SS, PRIYADARSHI RN, et al. Sarcopenia in chronic liver disease: A metabolic perspective[J]. J Clin Transl Hepatol, 2022, 10( 6): 1213- 1222. DOI: 10.14218/JCTH.2022.00239.
    [39]
    GREGORY PB, KNAUER CM, KEMPSON RL, et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo[J]. N Engl J Med, 1976, 294( 13): 681- 687. DOI: 10.1056/NEJM197603252941301.
    [40]
    FUJIWARA K, YASUI S, HAGA Y, et al. Early combination therapy with corticosteroid and nucleoside analogue induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus infection[J]. Intern Med, 2018, 57( 11): 1543- 1552. DOI: 10.2169/internalmedicine.9670-17.
    [41]
    ZHAO J, ZHANG JY, YU HW, et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J]. Cell Mol Immunol, 2012, 9( 5): 417- 422. DOI: 10.1038/cmi.2011.51.
    [42]
    HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20( 1): 38- 44. DOI: 10.1111/1751-2980.12691.
    [43]
    JIA L, XUE R, ZHU YK, et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: A prospective multi-center clinical trial[J]. BMC Med, 2020, 18( 1): 383. DOI: 10.1186/s12916-020-01814-4.
    [44]
    XUE R, MENG QH. The management of glucocorticoid therapy in liver failure[J]. Front Immunol, 2019, 10: 2490. DOI: 10.3389/fimmu.2019.02490.
    [45]
    ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2020, 3( 1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
    [46]
    CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9( 12): 2632. DOI: 10.3390/cells9122632.
    [47]
    CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18( 5): 403- 411. DOI: 10.1016/j.hbpd.2019.07.003.
    [48]
    XU Y, JIANG YF, LI Y. Outcomes of glucocorticoid treatment in HBVAssociated acute-on-chronic liver failure patients: A retrospective observational study[J]. Turk J Gastroenterol, 2021, 32( 5): 473- 480. DOI: 10.5152/tjg.2021.20257.
    [49]
    WU ZB, WANG K, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 5): 101505. DOI: 10.1016/j.clinre.2020.07.010.
    [50]
    SHI P, ZHU WT, LIANG A, et al. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Acta Gastroenterol Belg, 2022, 85( 4): 593- 600. DOI: 10.51821/85.4.10728.
    [51]
    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.

    中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
    [52]
    OCAK I. A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous venovenous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation[J]. Ann Transplant, 2023, 28: e939745. DOI: 10.12659/AOT.939745.
    [53]
    WANG L, XU WX, ZHU S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: A prospective study[J]. J Clin Transl Hepatol, 2023, 11( 4): 908- 917. DOI: 10.14218/JCTH.2022.00254.
    [54]
    XU WX, ZHU S, YANG L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure[J]. J Med Virol, 2023, 95( 3): e28650. DOI: 10.1002/jmv.28650.
    [55]
    MAIWALL R, BAJPAI M, SINGH A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2022, 20( 4): e831- e854. DOI: 10.1016/j.cgh.2021.01.036.
    [56]
    HIRANO R, NAMAZUDA K, HIRATA N. Double filtration plasmapheresis: Review of current clinical applications[J]. Ther Apher Dial, 2021, 25( 2): 145- 151. DOI: 10.1111/1744-9987.13548.
    [57]
    LIU H, ZHANG Q, LIU L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Artif Organs, 2020, 44( 10): E434- E447. DOI: 10.1111/aor.13710.
    [58]
    YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34( 4): 392- 398. DOI: 10.1002/jca.21690.
    [59]
    ZHOU L, CHEN Y. Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure[J]. Chin J Hepatol, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008.

    周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准[J]. 中华肝脏病杂志, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2215) PDF downloads(389) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return